We are live on ! Find out more
SILO icon

Silo Pharma

16 hedge funds and large institutions have $168K invested in Silo Pharma in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

33% more funds holding

Funds holding: 12 → 16 (+4)

3.54% less ownership

Funds ownership: 7.8% → 4.26% (-3.5%)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

71% less capital inflows, than outflows

Capital inflows: $66.8K | Capital outflows: $231K

Holders
16
Holders Change
+4
Holders Change %
+33.33%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
2
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

SILO Hedge Fund Activity: Q4 2024 in Review

16 of the 7,624 institutional investors tracked by Wall St. Rank reported a position in Silo Pharma (SILO) for Q4 2024, worth a combined $168K — down 56% from $383K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new SILO positions and 1 closed out — a net gain of 4 holders — while 2 added to existing stakes and 4 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $20.7K. The largest seller was Renaissance Technologies, cutting an estimated $195K.

  • 16 institutional investors held Silo Pharma (SILO) as of Q4 2024, up from 12 in Q3 2024.
  • Funds reported $168K of Silo Pharma stock for Q4 2024, down 56% quarter-over-quarter.
  • 5 funds opened new Silo Pharma positions in Q4 2024 and 1 closed out, a net change of +4 holders.
  • The largest Silo Pharma buyer in Q4 2024 was UBS Group, an estimated $20.7K added.
  • The largest Silo Pharma seller in Q4 2024 was Renaissance Technologies, an estimated $195K sold.

Based on aggregated 13F filings for Q4 2024.